Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Global Phase 3 Study Of IMC-1121B In Metastatic Breast Cancer Commences
http://www.medicalnewstoday.com/articles/118498.php
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that the first patient has been treated in a global Phase 3 clinical trial of IMC-1121B, its anti-vascular endothelial growth factor receptor-2 (VEGFR-2) IgG1 monoclonal antibody, in women with metastatic breast cancer.
Breast Cancer Patient Advocates Concerned About Relationship With Genentech If Acquired By Roche
http://www.medicalnewstoday.com/articles/118446.php
<BR />Advocates, including those for breast cancer patients, are concerned about their relationship with pharmaceutical company <A href="http://www.gene.com/gene/index.jsp?q=Genentech&rls=com.
----------------------------------------------
** CANCER / ONCOLOGY News **
Biomedical Foundation Supports Technology Aimed At Destroying Cancer Cells
http://www.medicalnewstoday.com/articles/118557.php
A new technology, using electric pulses to destroy cancer tissue and named by NASA Tech Briefs as one of seven key technological breakthroughs of 2007, is receiving additional support aimed at moving the procedure to the marketplace.
Evidence Of Activity Seen In New Data From ASA404 Prostate Cancer Trial
http://www.medicalnewstoday.com/articles/118549.php
Antisoma plc (LSE: ASM; USOTC: ATSMY) announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.
Cancer - Spectrum Pharmaceuticals Launches FUSILEV For Injection
http://www.medicalnewstoday.com/articles/118513.php
Spectrum Pharmaceuticals, Inc., (NasdaqGM: SPPI) launched FUSILEV™ (levoleucovorin) for injection. "The launch of FUSILEV establishes the foundation of Spectrum's commercial oncology franchise," said Rajesh C.
Results From The PRECISION V Clinical Trial
http://www.medicalnewstoday.com/articles/118486.php
Biocompatibles is pleased to announce the headline results from the PRECISION V clinical trial. A more complete presentation of the results will take place as planned at CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 2008, September 13-17, 2008, Copenhagen.
Scientists Make Precancerous Cells Self-Destruct By Amplifying Cell Death Signals
http://www.medicalnewstoday.com/articles/118469.php
When a cell begins to multiply in a dangerously abnormal way, a series of death signals trigger it to self-destruct before it turns cancerous. Now, in research <i>Genes & Development</i>, Rockefeller University scientists have figured out a way in mice to amplify the signals that tell these precancerous cells to die.
Potential New Treatments For Deadly Cancer Which Primarily Strikes Infants
http://www.medicalnewstoday.com/articles/118466.php
Neuroblastoma is one of the most devastating diagnoses a child can receive. The cancer's victims average 2 years old when the disease is detected, most often by a parent feeling a lump in a child's abdomen.
Minority Patients Who Perceive Discrimination By Health Care Providers Less Likely To Seek Cancer Screenings, Study Finds
http://www.medicalnewstoday.com/articles/118460.php
Members of minority groups who perceive racial discrimination from their health care providers are less likely to be screened for breast or colon cancers, according to a recent study published in the journal <cite>Cancer Epidemiology, Biomarkers and Prevention</cite>, <a href="http://www.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
Damaging Effects Of Cigarette Smoke Mimicked By Newly Detected Air Pollutant
http://www.medicalnewstoday.com/articles/118531.php
A previously unrecognized group of air pollutants could have effects remarkably similar to harmful substances found in tobacco smoke, Louisiana scientists are reporting in a study scheduled for presentation at the 236th National Meeting of the American Chemical Society.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
The Multiple Myeloma Research Consortium Announces Initiation Of First Four-Drug Combination Study To Treat Newly Diagnosed Multiple Myeloma Patients
http://www.medicalnewstoday.com/articles/118491.php
The Multiple Myeloma Research Consortium (MMRC) announced the initiation of a four-drug combination study with REVLIMID® (lenalidomide), VELCADE® (bortezomib) for Injection, DOXIL® (doxorubicin HCl liposome injection) and dexamethasone for the treatment of multiple myeloma in patients who are previously untreated.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
Evidence Of Activity Seen In New Data From ASA404 Prostate Cancer Trial
http://www.medicalnewstoday.com/articles/118549.php
Antisoma plc (LSE: ASM; USOTC: ATSMY) announced survival data from its phase II study of ASA404 in hormone-refractory prostate cancer, in which patients were randomised to receive either 1200 mg/m2 ASA404 plus the chemotherapy drug docetaxel or a control treatment of docetaxel alone.
Alternative Vaccine Strategy Shows Promise In Prostate Cancer Patients
http://www.medicalnewstoday.com/articles/118532.php
New research indicates that giving patients a continuous low dose of an immune system booster, a method known as metronomic dosing, as part of a therapeutic prostate cancer vaccine strategy is safe and produces similar immune responses and fewer side effects than the more common dosing method, which is not well tolerated by many patients.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment